11.07.2015 Views

Clinical Textbook of Addictive Disorders 3rd ed - R. Frances, S. Miller, A. Mack (Guilford, 2005) WW

Clinical Textbook of Addictive Disorders 3rd ed - R. Frances, S. Miller, A. Mack (Guilford, 2005) WW

Clinical Textbook of Addictive Disorders 3rd ed - R. Frances, S. Miller, A. Mack (Guilford, 2005) WW

SHOW MORE
SHOW LESS
  • No tags were found...

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

676 IndexMethamphetamine (cont.)neurophysiology, 11, 207–208preparation and administration, 206–207prevalence and patterns <strong>of</strong> use, 206tolerance, 2073, 4-Methylen<strong>ed</strong>ioxyamphetamine, 653, 4-Methylen<strong>ed</strong>ioxymethamphetamine(MDMA), 260–262, 419adolescent use patterns, 560laboratory testing for, 65Methylphenidate, 289–290, 560Michigan Alcoholism Screening Test,46, 399Microsomal ethanol-oxidizing system,84–85Military personnel, 351–352Mindfulness, 624–625Minnesota Model <strong>of</strong> treatment, 30Minnesota Multiphasic PersonalityInventory, 46–47, 49Mix<strong>ed</strong> substance abuse. SeePolysubstance abuseMonoamine oxidase, stimulusaugmentation and, 40Monoamine oxidase inhibitors, 201–202contraindications in cocaine abusers, 606for smoking cessation, 591Mood disordersin adolescents, 566–567alcohol use and, 79–80, 89gender differences, 253impulse control disorders and, 306Morphine, laboratory testing for, 65Mortalitycocaine-relat<strong>ed</strong>, 185gender differences, 446–447Native American, 332–333Motivational enhancement therapy, 496,515cocaine relapse prevention, 204–205Motivational interviewing, 641cocaine relapse prevention, 204–205with dually diagnos<strong>ed</strong> patients, 282Motor vehicle operationslegal liability <strong>of</strong> intoxicat<strong>ed</strong> persons, 358mandat<strong>ed</strong> reporting <strong>of</strong> substance use,350–351Multidimensional PersonalityQuestionnaire, 49–50Multidrug abuse. See Polysubstance abusemu opioid receptorsbuprenorphine action, 13in impulse control disorders, 307–308naltrexone action, 12–13Musculoskeletal system, alcohol effects, 95NNalmefene, 594Naloxone, 596–597Naloxone challenge, 600Naltrexone, 402, 405adolescent treatment, 575alcohol relapse prevention, 593–594cocaine abuse treatment, 202, 603–605effectiveness, 645–646for impulse control disorders, 309–312, 315, 316neurobiological action, 12–13for opioid relapse prevention, 600–601, 650–651for opioid withdrawal, 597Narcissism <strong>of</strong> addicts, 460, 508Narcotics Anonymous, 512–513National Institute on Alcohol Abuseand Alcoholism, 24National Institute on Drug Abuse, 24, 66National Institutes <strong>of</strong> Mental Health, 24Native Americans, 332–333alcohol use and abuse, 83population statistics, 321tobacco use, 105, 118Network therapy, 521–523Neurobehavioral disinhibition, 44–45Neurobiologyalcohol effects, 85–89, 93–94chronic pain, 376–377cocaine effects, 189–191, 197cognitive assessment, 50–51cognitive impairments associat<strong>ed</strong> withsubstance abuse, 40–42, 51implications for treatment <strong>of</strong>addiction, 3–4, 12–14

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!